Cancer update buoys Amgen despite Q2 sales fallAmgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but Share XCancer update buoys Amgen despite Q2 sales fallhttps://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/
CHMP says no to Amgen’s osteoporosis drug EvenityAmgen and UCB have suffered another setback as they try to build momentum for Evenity, their new antibody Share XCHMP says no to Amgen’s osteoporosis drug Evenityhttps://pharmaphorum.com/news/chmp-says-no-to-amgens-osteoporosis-drug-evenity/
At long last, Amgen/UCB score FDA okay for EvenityAmgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down Share XAt long last, Amgen/UCB score FDA okay for Evenityhttps://pharmaphorum.com/news/at-long-last-amgen-ucb-score-fda-okay-for-evenity/
Amgen and UCB re-file Evenity for US approvalAmgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that Share XAmgen and UCB re-file Evenity for US approvalhttps://pharmaphorum.com/news/amgen-ucb-evenity-fda-filing/
